Cyclacel acquires novel anticancer drug from Lorus Therapeutics

November 2003
PharmaWatch: Biotechnology;November 2003, Vol. 2 Issue 11, p22
Market Research Report
Reports on the acquisition of the anticancer drug CYC381 from the biotechnology firm Lorus Therapeutics Inc. by Cyclacel Ltd. Ability of the drug to arrest cancer cells; Terms of the agreement; Payment received by Lorus from the agreement.


Related Articles

  • Licensing News Headlines September 15, 2003 - October 14, 2003.  // PharmaWatch: Biotechnology;November 2003, Vol. 2 Issue 11, p21 

    Reports developments related to contracts in the biotechnology sector from September 2003 to October 2003. Collaboration between Acambis PLC and George Mason University; Termination of the partnership between AstraZeneca PLC and NicOx SA; Acquisition of the anticancer drug from Lorus...

  • FDA APPROVES LORUS/NCI GTI-2040 PHASE II CLINICAL TRIAL.  // Worldwide Biotech;Oct2003, Vol. 15 Issue 10, p1 

    Reports on the announcement of Lorus Therapeutics Inc. that the U.S. Food and Drug Administration has approved the U.S. National Cancer Institute's Investigational New Drug Application to begin a Phase II clinical trial to investigate Lorus' lead antisense drug for breast cancer, as of October 2003.

  • Lorus and BioVectra sign pancreatic cancer drug deal.  // PharmaWatch: Biotechnology;January 2005, Vol. 4 Issue 1, p14 

    Reports on the commercial supply agreement between Lorus Therapeutics Inc. and BioVectra DCL company for pancreatic cancer candidate Virulizin. Completion of the technology transfer process to BioVectra; Evaluation on the use of Virulizin as a treatment of advanced pancreatic cancer in...

  • Clinic Roundup.  // BioWorld Today;1/14/2011, Vol. 22 Issue 10, p5 

    The article reports that Lorus Therapeutics Inc. has enrolled the first cancer patient in a Phase I study to evaluate its small-molecule anticancer drug candidate LOR-253.

  • FINANCINGS ROUNDUP.  // BioWorld Today;6/7/2010, Vol. 21 Issue 108, p6 

    This section offers news briefs concerning finances of biotechnology companies, which include the repurchase of outstanding common stock by BioSpecifics Technologies Corp. and the filing of a registration statement by Lorus Therapeutics Inc.

  • Financings Roundup.  // BioWorld Today;11/11/2010, Vol. 21 Issue 219, p4 

    The article presents an update on the financing efforts of several biotechnology companies as of November 11, 2010, including Biodesix Inc., Cerus Corp. and Lorus Therapeutics Inc.

  • AACR Roundup.  // BioWorld Today;4/5/2011, Vol. 22 Issue 65, p8 

    The article focuses on the preclinical data presented by Lorus Therapeutics Inc. at the annual meeting of the American Association for Cancer Research (AACR) on lead small molecule LOR-253 as an inhibitor of growth of non-small-cell lung cancer in both in vitro and animal models.

  • R&D Update -- Other Cancers.  // PharmaWatch: Cancer;March 2003, Vol. 2 Issue 3, p11 

    Reports developments in research and development related to cancer treatment as of February 2003. Approval of the Data Safety Monitoring Board to the continuation of the thymitaq liver cancer trial of Eximias Pharmaceutical Corp.; Expansion of the renal cell carcinoma trial of Lorus Therapeutics...

  • INDUSTRY UPDATE - Other Cancers.  // PharmaWatch: Cancer;April 2003, Vol. 2 Issue 4, p14 

    Reports developments related to cancer as of March 2003. Positive opinion received by Novartis AG from European regulators at the Committee for Proprietary Medicinal Products over a label update for its Zometa drug; Patent granted to protect the R1 component of ribonucleotide reductase of Lorus...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics